Sign In

Michael Heltzen

Biology as Technology expert

Michael Heltzen is the Chief Executive Officer of Invizyne Technologies, a company specializing in enzyme-based biomanufacturing systems. His appointment was announced in May 2024, as Invizyne prepares for its public offering and aims to revolutionize the production of essential chemicals and molecules through innovative biomanufacturing techniques.14

Professional Background:: Before joining Invizyne, Heltzen held several significant positions:

  • Executive Vice President for Strategy at Paragraf Ltd.
  • Chief Executive Officer of Cardea Bio Inc.
  • Chief Executive Officer and Chairman of Nanosens Innovations Inc., prior to its merger with Cardea Bio.1

Heltzen has over 20 years of experience in global commercial leadership and is recognized for his ability to launch and grow technology-driven companies. His focus has been on integrating biology with technology, particularly in the fields of bioinformatics and genomics.23

Philosophy and Vision:: Heltzen is passionate about the "Biology as Technology" movement, which merges biological sciences with digital computing, aiming to create innovative solutions in life sciences. He emphasizes building strong corporate cultures and empowering teams to drive innovation within the biotech industry.2

Education and Skills:: His background includes extensive experience in strategic development, business optimization, and international negotiations. Heltzen is fluent in English and Danish, with limited proficiency in German.2

Overall, Michael Heltzen's leadership at Invizyne is expected to leverage his extensive experience and vision to advance the company's mission in sustainable biomanufacturing.

Highlights

Aug 28 · linkedin

Amazing to see someone describing us/Invizyne, and nailing it:

"Invizyne Technologies: A Case Study in Innovation

Invizyne Technologies stands out as a trailblazer in the biomanufacturing industry, pushing the boundaries of what is possible with its innovative cell-free biomanufacturing platform, SimplePath. Founded in 2019, Invizyne has focused on creating more efficient and sustainable methods for producing a wide range of chemicals, from pharmaceuticals to biofuels. Unlike traditional manufacturing methods that rely on living cells, Invizyne's platform uses enzymes directly to catalyze chemical reactions, bypassing many of the limitations associated with cellular processes. This breakthrough technology not only streamlines production but also significantly reduces waste, making it a key player in the movement toward greener and more adaptable biomanufacturing solutions. Through its partnerships and focus on commercializing new technologies, Invizyne is at the forefront of revolutionizing chemical production for a more sustainable future."

  • From: Navigating the Frontier of Biomanufacturing: Innovations Driving a New Era of Production:
Aug 22 · linkedin

I still think AI/ML should be called Pattern Recognition or Pattern Discovery (1)!

And now, with Wolfram's aha moment about AI/ML, I will argue that even more.

  • I think it is cool Wolfram (released to just now) helps us to understand (why we will not understand!) how AI/ML works, at least not the way we like to understand it :) His main point is that it takes "Computational Irreducibility" as the trick to make sure the math does not get stuck (in the Pattern Modeling/Matching/Statistics/Projection/Discovery/Recognition/ML/AI).

Jason Steiner - this is what we talked about the other day regarding it is not about having a lot of data (only) or the best algorithm, it is about having (reactive) data that has enough (multi-perspective) signal in the data, so the algorithm can find "math patterns" that fits the reality signals...

  1. Pattern Discovery was what we called it back 15+ years ago at CLC bio (based on HMM instead of modern NN, admittedly): https://lnkd.in/gQyQ2xS5 )

Related Questions

What are Michael Heltzen's key achievements at Cardea Bio Inc?
How did Michael Heltzen's role at Paragraf Ltd influence his strategy at Invizyne?
What is the significance of Invizyne's IPO registration statement?
How does Michael Heltzen's international experience impact his leadership at Invizyne?
What are the main goals of Invizyne's cell-free, enzyme-based biomanufacturing systems?
Michael Heltzen
Michael Heltzen, photo 1
Michael Heltzen, photo 2
Add to my network

Experience

Chief Strategy Officer at Invizyne (October 2023 - Present)
EXO Incubator (September 2015 - Present), BlueSEQ Innovations Inc. (September 2010 - Present), Chairman, CEO & Lead Investor at Nanosens Innovations Inc. (December 2018 - September 2019), "Mayor of In at Startup City Denmark (August 2011 - August 2015)

Location

United States